Zach Berman MD
Zach Berman MD
Oncology has seen remarkable advances, yet many patients remain without durable responses. My work spans three intersecting domains — each aimed at improving both the rate and the depth of response for patients with hepatobiliary and other solid malignancies.
I am an Associate Professor of Clinical Radiology at the University of California, San Diego, with a subspecialty focus in interventional oncology and hepatobiliary malignancies. I completed my diagnostic and interventional radiology residency at UC San Diego, following an internal medicine internship there as well, after earning my MD at Case Western Reserve University School of Medicine and a BA in Economics and Biochemistry from Oberlin College.
My clinical and academic career is built on a commitment to innovation in minimally invasive cancer therapy. I serve as a principal investigator on the TASER-HCC trial — a national multicenter phase 2 trial of single-session radioembolization for HCC — as well as site PI for CapTemY90, FRONTIER (TheraSphere for GBM), and the GPX Trial. I also hold investigator roles on more than a dozen additional trials combining locoregional and immunotherapy approaches.
Rapid Fire IO is my YouTube channel dedicated to concise, high-yield educational content in interventional oncology — journal clubs, technique breakdowns, trial reviews, and clinical pearls for IR physicians, fellows, and trainees.
New content drops regularly. Subscribe to stay current with the latest in IO, Y90 dosimetry, combination immunotherapy, and ablation.
Subscribe on YouTube
Advancing precision in image-guided tumor ablation through improved margin assessment, CT-guided robotic assistance, and dosimetric optimization — extending curative intent to patients previously considered inoperable.
Innovating voxel-based and personalized Y90 dosimetry for HCC and neuroendocrine tumors — moving from empirical dosing to predictive, ablative paradigms that drive complete pathologic necrosis and durable response.
Exploring the synergy between locoregional therapies and systemic immunotherapy — leveraging abscopal effects, tumor microenvironment modulation, and checkpoint inhibition to produce durable systemic responses.
I serve as principal or co-investigator on more than 15 clinical trials spanning locoregional therapy, immunotherapy combinations, and next-generation embolic devices. Selected active studies are listed below.
Whether you are a colleague interested in research collaboration, a trainee seeking mentorship, a conference organizer, or a referring physician — I welcome the conversation.